Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Children's Health Care, Diabetes Programs Funded In Short-Term US Measure

Executive Summary

Congress has passed a third continuing resolution bill to provide partial FY 2018 funding. The measure also supports the Children's Health Insurance Program and two special diabetes programs – all of which provide basic health care and diagnostics to the poor, while also supporting next-gen technology research – using dollars from a prevention and public health fund.

You may also be interested in...



Medtech Provisions Approved In US Budget Agreement

Medtech and funding provisions in a two-year budget deal that the US Senate and House approved early Friday morning and which were signed by the President would extend Medicate telehealth programs, remove a rental cap for speech-generating devices and strengthen competitive bidding rules to assure access to diabetic test strips, among others. 

US Congress Passes Short-Term Funding, While Debt Ceiling Lingers

Congress managed to temporarily stave off a government shutdown, but a continuing resolution bill passed Dec. 7 gives lawmakers only two more weeks – until Dec. 22 – to come up with a final budget plan for 2018. Meanwhile, a deal to raise the debt ceiling, allowing more spending next year, still needs to be set.

White House To Deliver 25 Million Face Masks To Low-Income Americans

The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT121980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel